文献速递类风湿关节炎

类风湿关节炎患者感染COVID-19奥密克戎变异株的结局:希腊全国性队列研究

Outcomes of COVID-19 Omicron variant in patients with rheumatoid arthritis: a nationwide Greek cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该研究在2022年1月1日至6月30日期间纳入希腊全国34182例类风湿关节炎患者,并按年龄、性别和居住地区1:5匹配一般人群对照,回顾性比较奥密克戎变异株流行期间的感染、住院和死亡结局。类风湿关节炎患者感染后住院风险(OR 2.02)和死亡风险(OR 1.73)仍升高,其中利妥昔单抗治疗与住院和死亡风险增加相关,JAK抑制剂与住院风险增加相关。

要点

  • 类风湿关节炎患者感染奥密克戎后住院率1.43%、死亡率0.31%,均高于匹配的一般人群对照。
  • 校正年龄、性别、疫苗接种、既往COVID-19和抗病毒药物后,类风湿关节炎患者住院OR 2.02、死亡OR 1.73。
  • 感染后的类风湿关节炎患者中,利妥昔单抗与住院(OR 6.12)和死亡(OR 12.06)风险增加相关,JAK抑制剂与住院风险增加相关(OR 2.18)。

核心结论

  • 在COVID-19病死率相对较低的奥密克戎时代,类风湿关节炎仍是住院和死亡的风险因素,作者指出需要坚持疫苗接种规划并更广泛使用抗病毒药物。

研究设计与样本

  • 回顾性全国性研究,于2022年1月1日至2022年6月30日开展,纳入所有在接受治疗的类风湿关节炎患者,并按年龄、性别和居住地区以1:5匹配随机一般人群对照。
  • 共纳入34182例类风湿关节炎患者,记录确诊SARS-CoV-2感染、住院、死亡、抗风湿药物、既往COVID-19、疫苗接种和抗病毒药物。

主要发现

  • 类风湿关节炎患者中感染5569例(16.29%)、住院489例(1.43%)、死亡106例(0.31%),均较对照更常见。
  • 每1000人年发病率:感染IRR 1.19(95%CI 1.16, 1.23)、住院IRR 2.0(95%CI 1.82, 2.24)、死亡IRR 1.81(95%CI 1.44, 2.27),类风湿关节炎组均升高,尽管其疫苗接种覆盖率更高(89% vs 84%)且抗病毒药物使用更频繁(2.37% vs 1.08%)。
  • 在感染的类风湿关节炎患者与对照中,校正年龄、性别、疫苗接种、既往COVID-19和抗病毒药物后,类风湿关节炎组住院风险OR 2.02(95%CI 1.79, 2.27)、死亡风险OR 1.73(95%CI 1.36, 2.20)升高。
  • 感染的类风湿关节炎患者中,利妥昔单抗治疗与住院风险OR 6.12(95%CI 2.89, 12.92)和死亡风险OR 12.06(95%CI 3.90, 37.31)增加相关,JAK抑制剂仅与住院风险增加相关(OR 2.18,95%CI 1.56, 3.06)。

临床怎么用

  • 作者结论指出,类风湿关节炎仍是住院和死亡的风险因素,需要坚持疫苗接种规划并更广泛使用抗病毒药物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients with RA were at increased risk for COVID-19-associated hospitalization and death during the first year of the pandemic in Greece. We aimed to examine their outcomes after the SARS-Cov-2 Omicron, a more contagious but with milder clinical impacts variant, prevailed. METHODS: A retrospective, nationwide study was conducted between 1 January 2022 and 30 June 2022 in all RA patients under treatment and matched (1:5) on age, sex and region of domicile random general population comparators. Confirmed SARS-CoV-2 infections, hospitalizations and deaths, anti-rheumatic medications, prior COVID-19, vaccinations and anti-viral medications were recorded. RESULTS: Among 34 182 RA patients, infections (n = 5569, 16.29%), hospitalizations (n = 489, 1.43%) and deaths (n = 106, 0.31%) were more frequent than among comparators. Incidence rates per 1000 person/years of infection [IRR (95% CI):1.19 (1.16, 1.23)], hospitalization [IRR (95% CI):2.0 (1.82, 2.24)], and death [IRR (95% CI):1.81 (1.44, 2.27)] were increased in RA despite better vaccination coverage (89% vs 84%) and more frequent use of anti-viral medications (2.37% vs 1.08). Logistic regression analysis after correcting for age, sex, vaccinations, prior COVID-19, and anti-viral medications in SARS-CoV-2 infected RA patients and comparators revealed increased risk of hospitalization (OR: 2.02, 95% CI: 1.79, 2.27) and death [OR: 1.73, (95% CI: 1.36, 2.20)] in RA. Among infected RA patients, rituximab treatment conferred increased risks for hospitalization [OR: 6.12, (95% CI: 2.89, 12.92)] and death [OR: 12.06 (95% CI: 3.90, 37.31)], while JAK inhibitors increased only hospitalization risk [OR: 2.18 (95% CI: 1.56, 3.06)]. CONCLUSION: RA remains a risk factor for hospitalization and death in an era of a relatively low COVID-19 fatality rate, pointing to the need of perseverance in vaccination programs and wider use of anti-viral medications.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Bournia VK, Fragoulis GE, Mitrou P, et al. Outcomes of COVID-19 Omicron variant in patients with rheumatoid arthritis: a nationwide Greek cohort study. Rheumatology (Oxford). 2024. PMID: 37467059. doi:10.1093/rheumatology/kead354

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。